Recent Updates — MNMD

Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder. The trial met all primary and key secondary efficacy endpoints, demonstrating a statistically significant placebo-adjusted reduction in Hamilton Anxiety Rating Scale (HAM-A) scores of 5.4 points at Week 12 (p<0.0001). The drug was generally well tolerated with no new safety signals identified. Definium Therapeutics is a late-stage clinical biopharmaceutical company developing psychedelic-inspired therapeutics for psychiatric and neurological disorders.

Definium Therapeutics reported second quarter 2026 financial results and announced positive topline results from its Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), meeting primary and secondary efficacy endpoints with a statistically significant improvement in MADRS scores. The company completed an underwritten public offering of approximately 23.7 million common shares for $805 million in gross proceeds, bringing cash, cash equivalents, and investments to $1.1 billion as of June 30, 2026. Net loss for the quarter was $159.0 million, significantly impacted by an $86.2 million non-cash increase in warrant liability fair value. The company also provided updates on its pipeline, including completed enrollment in Phase 3 Voyage and Panorama studies for generalized anxiety disorder (GAD) and initiated enrollment in the Phase 3 Ascend study for MDD. Definium Therapeutics is a late-stage clinical biopharmaceutical company developing psychedelic therapeutics for psychiatric disorders.